The clinical benefits of targeting FcεRIβ have been ambiguous, since the association of MS4A2 polymorphisms with allergy and asthma is not consistent [116,117,118] and transfection of MS4A2 cDNA containing mutations associated with asthma has previously failed to alter FcεRIβ function [119,120]. Here, MS4A2 is linked to allergic disease.